ZyVersa: Protecting Pancreatic Islet Beta Cells, Curbing Progress from Obesity to Insulin Resistance, T2D

 

• During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells.
• Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development of type 2 diabetes.
• The published data showed that inflammasome NLRP3 inhibition was protective of pancreatic islet beta cells, restoring their function and improving metabolic status in an obesity DIO mouse model.
• Data from this article support ZyVersa’s development of Inflammasome ASC Inhibitor IC 100 for obesity and its associated comorbidities to be used as an add-on to incretin therapy.

https://www.globenewswire.com/news-release/2024/11/05/2974772/0/en/ZyVersa-Therapeutics-Highlights-Published-Data-Demonstrating-the-Potential-of-Inflammasome-Inhibition-to-Protect-Pancreatic-Islet-Beta-Cells-and-Attenuate-Progression-from-Obesity-.html